Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation
about
Erdheim-Chester Disease: a comprehensive review of the literatureCardiovascular Involvement in Erdheim-Chester Disease: A Case Report and Review of the LiteratureSmoking-related interstitial lung diseaseVemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.Somatic mutations in solid tumors: a spectrum at the service of diagnostic armamentarium or an indecipherable puzzle? The morphological eyes looking for BRAF and somatic molecular detections on cyto-histological samplesInsights into the pathogenesis of Langerhans cell histiocytosis: the development of targeted therapiesEmerging platforms using liquid biopsy to detect EGFR mutations in lung cancerInterleukin-1 loop model for pathogenesis of Langerhans cell histiocytosisCell(s) of Origin of Langerhans Cell HistiocytosisThe 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and ChangesConsensus guidelines for the diagnosis and clinical management of Erdheim-Chester diseaseErdheim–Chester DiseaseClinical and Radiologic Responses to Cladribine for the Treatment of Erdheim-Chester Disease.Diffuse Cystic Lung Disease. Part I.BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester diseaseA common progenitor cell in LCH and ECD.Potential clinical implications of BRAF mutations in histiocytic proliferations.Driving toward targeted therapy for LCH.Langerhans cell histiocytosis of the thyroid with multiple cervical lymph node involvement accompanying metastatic thyroid papillary carcinoma.Recurrent RAS and PIK3CA mutations in Erdheim-Chester diseaseLangerhans cell histiocytosis in children: from the bench to bedside for an updated therapy.Clinical considerations and key issues in the management of patients with Erdheim-Chester Disease: a seven case series.Pediatric lymphomas and histiocytic disorders of childhoodClinicopathologic characteristics and outcomes of histiocytic and dendritic cell neoplasms: the moffitt cancer center experience over the last twenty five years.A framework for genomic biomarker actionability and its use in clinical decision makingFrequent detection of BRAF(V600E) mutations in histiocytic and dendritic cell neoplasms.Erdheim-Chester disease: from palliative care to targeted treatment.Excellent response of intramedullary Erdheim-Chester disease to vemurafenib: a case report.BRAF Mutations in Canine Cancers.How I treat Langerhans cell histiocytosis.High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experienceDetection of BRAF Mutation in Urine DNA as a Molecular Diagnostic for Canine Urothelial and Prostatic CarcinomaEosinophilic granuloma/Langerhans cell histiocytosis: Pediatric neurosurgery update.Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1.A Unique Case of Erdheim-Chester Disease with Axial Skeleton, Lymph Node, and Bone Marrow InvolvementDiverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.Diabetes insipidus, bone lesions, and new-onset red-brown papules in a 42-year-old man.Langerhans Cell Sarcoma Arising from Chronic Lymphocytic Lymphoma/Small Lymphocytic Leukemia: Lineage Analysis and BRAF V600E Mutation StudyUnusual presentation of Erdheim-Chester disease in a child with acute lymphoblastic leukemia.Long-term outcome of basilar stenosis in Erdheim-Chester disease: A case report.
P2860
Q21202851-768F53F8-6C6B-49EC-9C72-B06442FE681BQ26778060-D2D468CD-19DC-4043-8E57-D5F07DA24BB2Q27027779-9C34A864-6A1D-4CA0-BF05-94CD0E8D4B17Q27853199-F89AADC7-B078-4C8B-8839-4F94DB7A008FQ28070226-73598A75-3A31-4B2C-BE7C-0ABE3811D0D1Q28071258-234F9F43-311A-43F2-B99C-999D221A0B7EQ28082499-BDA65D19-C72C-4849-B5D7-81D78C90831DQ28083455-1D59FD8A-D284-459E-830B-4065717D7F7AQ28087231-1FC563B4-16F9-440E-A5B4-A2EC50C81FF0Q28087370-06C10D90-A595-4E83-8885-DD1FD656C9FCQ28240576-B2A80BF6-B460-4EE3-9407-6E017F03B893Q30047444-F3E1881C-C149-41B5-9DF6-07142D42345BQ33439784-C0A2AA46-F828-4BF1-8A7A-89BF7F45633CQ33722950-9D32EE4A-AF25-4C47-ACD6-23CF21398244Q33976971-E59156AA-2B1E-4E05-BD8B-36D316AE3F62Q34047939-81F1A16A-0D2A-4510-8807-DD90421B1C1FQ34100859-6B3F1C8E-0FCA-4FED-BD86-373F7F8AE009Q34136966-486F5F1D-1D6F-4668-BB3E-05A5B1FB9DE9Q34366295-FF383CC6-980F-48B9-9086-6439430EA41FQ34471821-0B3DAE91-5D30-47AF-BAD8-23AFEF4B2C49Q34515611-F6BA1555-6337-44B7-98E3-9B8B97FD946AQ34591365-E3E65792-EC21-4FF8-9918-A2B3A9C10F7AQ34605894-97D5034F-0D23-44F9-8244-56E444758C6AQ34774902-6D5C0D46-F458-413A-8DA2-6B04F07B119CQ34781122-F90B4992-2D57-4548-BF81-98F3DBB5C423Q35144523-5A00FDA2-3649-448E-B213-5C8B0C0962FDQ35227699-DB4EA274-2D0A-4A4A-9AFA-44B42C2BF112Q35618455-B73E0805-F9B5-43FE-82B4-B7CD39CB2B19Q35656395-CD4CE718-26A7-4BAF-815C-B0AF705C79F0Q35820361-436912B1-AA48-4412-84CD-882BF641C998Q35836477-16D126F8-7326-4A40-84FF-FAC48148F2D6Q35864031-6C4B9F38-C956-4520-941C-ABA83F118E17Q36159327-D86C9681-124F-4913-A357-CDE60EA09060Q36260647-EC72A2D2-1800-4CE6-880E-F67553E728A5Q36482488-58F85B0D-F3C0-421D-85AF-1DE57B090BACQ36553791-45B109CC-FBD3-477B-9E24-500731B5123CQ36853339-709F51F2-CA62-4219-8CD6-7E33E717C30DQ37065531-DCA84BB4-2806-46CE-B61A-CFF24E75EDE9Q37212686-D1020159-66B1-459A-8564-477678E1D6B6Q37257050-8E9BA4FE-46BA-4657-B581-5231B163936F
P2860
Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation
description
2013 nî lūn-bûn
@nan
2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Dramatic efficacy of vemurafen ...... boring the BRAF V600E mutation
@ast
Dramatic efficacy of vemurafen ...... boring the BRAF V600E mutation
@en
Dramatic efficacy of vemurafen ...... boring the BRAF V600E mutation
@nl
type
label
Dramatic efficacy of vemurafen ...... boring the BRAF V600E mutation
@ast
Dramatic efficacy of vemurafen ...... boring the BRAF V600E mutation
@en
Dramatic efficacy of vemurafen ...... boring the BRAF V600E mutation
@nl
prefLabel
Dramatic efficacy of vemurafen ...... boring the BRAF V600E mutation
@ast
Dramatic efficacy of vemurafen ...... boring the BRAF V600E mutation
@en
Dramatic efficacy of vemurafen ...... boring the BRAF V600E mutation
@nl
P2093
P3181
P1433
P1476
Dramatic efficacy of vemurafen ...... boring the BRAF V600E mutation
@en
P2093
Aurélie Drier
Baptiste Hervier
Fleur Cohen-Aubart
Frédéric Charlotte
Jean Donadieu
Jean-François Emile
Laurent Arnaud
Neïla Benameur
Philippe Cluzel
Philippe Maksud
P304
P3181
P356
10.1182/BLOOD-2012-07-446286
P407
P577
2013-02-28T00:00:00Z